Allogeneic, mesenchymal stem cells (ALOFISEL) are effective in eradicating complex peri-anal fistulas in Crohn’s disease
Drug profileGastroent Hepatol 2019; 73(6): 553–554. doi:10.14735/amgh2019553
Literaturepdf Milan LukášAsacol 1.6 g uses the new technology concept OPTICORE™
Drug profileGastroent Hepatol 2019; 73(5): 455–456. doi:10.14735/amgh2019455
Literaturepdf Milan LukášTofacitinib – the first JAK inhibitor in the treatment of ulcerative colitis. Beginning of the therapeutic era of „small molecules“ in inflammatory bowel disease?
Drug profileGastroent Hepatol 2019; 73(4): 363–365. doi:10.14735/amgh2019363
Literaturepdf Milan LukášHeme iron in substitution of sideropenia and sideropenic anemia
Drug profileGastroent Hepatol 2019; 73(3): 271–272. doi:10.14735/amgh2019271
Literaturepdf Milan LukášBiosimilar adalimumab FKB327 (Hulio®)
Drug profileGastroent Hepatol 2019; 73(2) 177–178. doi:10.14735/amgh2019177
Literaturepdf Milan LukášClensia® – the first combined cleansing agent with simeticone
Drug profileGastroent Hepatol 2019; 73(1): 87–88. doi:10.14735/amgh201987
Literaturepdf Luděk HrdličkaFirst biosimilar adalimumab – SB5
Drug profileGastroent Hepatol 2018; 72(6): 551–552. doi:10.14735/amgh2018551
Literaturepdf Milan LukášPantoprazol in clinical praxis
Drug profileGastroent Hepatol 2018; 72(5): 458–460. doi:10.14735/amgh2018458
Literaturepdf Milan LukášMethotrexate – rediscovered drug for Crohn’s disease
Drug profileGastroent Hepatol 2018; 72(4): 367–368. doi:10.14735/amgh2018367
Literaturepdf Milan LukášVistaprep – the standard of bowel preparation before colonoscopy
Drug profileGastroent Hepatol 2018; 72(3): 273–274. doi:10.14735/amgh2018273
Literaturepdf Milan Lukáš